Thomsen named to receive the Thomas A. Hazinski, M.D., Scholarship
Isaac Thomsen, M.D., a fellow in Pediatric Infectious Disease, has been named as the fifth annual recipient of the Thomas A. Hazinski, M.D., Scholarship.
The Hazinski Scholarship was developed with the goal of providing support to promising Master of Science in Clinical Investigation applicants who have dedicated themselves to patient-oriented research. Excellence in research, outstanding mentorship and environment, and dedication to patient-oriented research were chief award criteria.
Thomsen works in the Vanderbilt Vaccine Research Program conducting clinical trials of new vaccines and therapeutics. His primary MSCI research project focuses on the adaptive immune response to staphylococcal disease in children, particularly those caused by methicillin-resistant S. aureus (MRSA).
Thomsen is currently enrolling children admitted to the Monroe Carell Jr. Children's Hospital at Vanderbilt with invasive S. aureus disease, seeking to characterize the basic elements of the early adaptive immune response to this common bacterial infection.
Thomsen’s work on the immune response to S. aureus is a natural extension of work he conducted during his residency in internal medicine and pediatrics at Vanderbilt, studying the molecular epidemiology of MRSA in children.
Thomsen will be mentored by Buddy Creech, M.D., MPH, assistant professor of Pediatric Infectious Diseases and associate director of the Vanderbilt Vaccine Research Program.
Thomsen said his MSCI training will strengthen his research and advance his career. “The MSCI program will provide me with the necessary skills to be a successful translational scientist in Pediatric Infectious Diseases.
"The goal of the MSCI – to train young investigators in epidemiology, clinical trials, and translational science – is ideally suited for my own professional goals, and I am excited to be a part of such a respected and successful program.”
For more information about the MSCI program, go to www.mc.vanderbilt.edu/msci.